PLGA from Akina, Inc. used in development of microneedle patches for transdermal delivery of biologics.

 

Microneedles are a series of small, polymeric pointed features that penetrate the skin very slightly and allow for transdermal drug delivery. Researchers at University of Missouri-Kansas City used PLGA (Cat# AP320, https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AP320#h) from PolySciTech : Akina, Inc. (www.PolySciTech.com) to develop microneedles loaded with peptides or proteins. This research holds promise to provide for transdermal delivery of these medicines. Read more: Hasan, Reaid, Yuhan Guo, Zhen Zhao, Yongren Li, Umar-Farouk Mamani, and Kun Cheng. "An Emulsion-Based Microneedle Formulation for Transdermal Delivery of Peptide Therapeutics." ACS Biomaterials Science & Engineering (2025). https://pubs.acs.org/doi/abs/10.1021/acsbiomaterials.5c01566

“Polymeric microneedle patches represent a promising noninvasive platform for the transdermal delivery of peptide and protein therapeutics, and FDA-approved polymers are widely used for this purpose. However, maintaining peptide and protein stability during microneedle fabrication remains a significant challenge. Conventional strategies involve encapsulating within polymer nanoparticles/microparticles, or codissolving them with polymers in organic solvents before microneedle fabrication. These approaches are time-consuming and often lead to low loading efficiency and drug loss. In this study, we developed a novel direct emulsion-based encapsulation strategy that integrates peptides within the PLGA matrix during microneedle formation. This approach generates a uniform water-in-oil (W/O) emulsion that ensures homogeneous peptide dispersion while minimizing interfacial stress, eliminating the need for multistep spraying or postloading processes. The optimized PLGA-based microneedles exhibited uniform geometry, high drug-loading capacity, and strong mechanical integrity suitable for skin penetration. The encapsulated peptide maintains its biological activity after fabrication and during storage, confirming excellent peptide stability. In vivo studies demonstrated successful skin insertion and sustained peptide release for up to 72 h, supporting the potential of this platform for prolonged transdermal peptide delivery. Overall, this work presents a scalable, biocompatible, and solvent-safe microneedle fabrication strategy that preserves peptide functionality while enabling controlled drug release, making it a promising strategy for transdermal peptide therapeutics.”

Benchtop to Bedside with MidWest GMP https://www.akinainc.com/midwestgmp/

Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

Ashland-TM Polymer Products: https://akinainc.com/polyscitech/products/ashland/